Skip to content

Depression research published in 2025

Page 19 of 39: studies 361 to 380 of 761, newest first. Back to the depression overview

Studies

MDMA-Assisted Treatment for PTSD, Anxiety, and Depression: A Visualized Literature Analysis over 30 Years.

Current Medicinal Chemistry June 2, 2025 Jinlong Zhang, Xingxing Dang, Jiang Lin et al.

The incidence of psychiatric disorders, such as post-traumatic stress disorder (PTSD), anxiety, and depression, has been steadily increasing, while current treatment approaches remain limited in efficacy. As a result, there is an urgent need to explore more effective therapeutic interventions. In recent years, MDMA (3,4- methylenedioxymethamphetamine)-assisted therapy (MDMA-AT) has emerged as a...

Mindfulness and Relaxation Interventions Reduce Depression, Negative Affect and Stress in Widow(er)s

Journal of Loss and Trauma June 1, 2025 Lindsey M. Knowles, Deanna M Kaplan, Melissa Flores et al.

Abstract Grief is a profound life stressor that impacts multiple psychological outcomes. Mind-body interventions like Mindfulness Training (MT) and Progressive Muscle Relaxation (PMR) show promise for addressing negative psychological sequelae of grief. The present study investigated the effects of MT and PMR on secondary outcomes of grief including depressive symptoms, negative and positive...

Nightmare frequency and nightmare distress in psychiatric inpatients.

European Archives of Psychiatry and Clinical Neuroscience June 1, 2025 Michael Schredl, Elisabeth Anzenberger, Claudia Schilling

Previous research indicated that the prevalence of frequent nightmares and/or the presence of a nightmare disorder is quite high in patients with mental disorders. In the present study, 75 randomly selected psychiatric inpatients were interviewed and completed questionnaires regarding nightmares, sleep, and psychopathology. The percentage of patients with nightmares once per week or more often...

DOI: 10.1007/s00406-024-01891-z (opens in new tab) Full text (opens in new tab) Depression Mental disorders Nightmare distress Nightmare frequency

Anhedonia Behavioural Activation and Ketamine Therapy (AAKT): Shaping a Proposal With Patient and Public Involvement

BJPsych Open June 1, 2025 Anna Borissova, Allan H. Young, Mitul A. Mehta et al.

Aims: Ketamine and behavioural activation (BA) reduce levels of anhedonia in major depressive disorder (MDD), though neither resolves anhedonia. Combining these treatments could yield additive or even multiplicative benefits. This poster summarises the development of a PhD fellowship proposal, discussing: (1) the initial patient and public involvement (PPI) interviews, exploring views on...

Sublingual Ketamine for Treatment Resistant Depression: Embracing the Change

BJPsych Open June 1, 2025 Ranjini Rao

Aims: 1. Examine efficacy and durability of antidepressant effects. 2. Identify specific symptoms of improvement. 3. Compare response rates and duration of antidepressant effects in failed to respond to previous treatments. Methods: Prospective review study of patients who received off-label rapid dissolve wafer for SL delivery in hospital setting 2–3 times a week for 4 weeks. The study...

Ketamine Cystitis Following Ketamine Therapy for Treatment Resistant Depression – Case Report

BJPsych Open June 1, 2025 Minna Chang, Allan H. Young, Mario F Juruena

Aims: Ketamine is a novel and exciting putative antidepressant medication for patients with treatment-resistant depression. A complication commonly seen in frequent and heavy recreational use of ketamine is ulcerative cystitis, which presents with lower urinary tract symptoms (LUTS) and upper renal tract damage and can be seen in over 25% of regular users. Although ketamine-induced cystitis...

Association Between Receipt of Ketamine vs Etomidate for Emergency Tracheal Intubation and Symptoms of Posttraumatic Stress Disorder at 12 Months.

CHEST critical care June 1, 2025 Lucas C Wollenman, Austin M Tipold, Matthew W. Semler et al. 1 citation

One of 3 patients in the ICU receiving mechanical ventilation demonstrates posttraumatic stress disorder (PTSD). A single dose of ketamine has been shown to reduce PTSD symptoms in outpatients with chronic PTSD, but its long-term effect is unknown in patients who are critically ill and mechanically ventilated. Is ketamine, when used for induction of anesthesia before emergency tracheal...

Exploring the Therapeutic Potential of Psilocybin and Ketamine in Major Depressive Disorder including Treatment-Resistant Depression: A Narrative Review

Biuletyn Głównej Biblioteki Lekarskiej June 1, 2025 Christian S. Skowron, Urszula Miłkowska, Gabriela Maria Piech et al.

Abstract Major depressive disorder (MDD), including treatment-resistant depression (TRD), represents significant global health challenges with conventional therapies often yielding suboptimal outcomes. This narrative review examines the therapeutic potential of psilocybin and ketamine, two novel agents offering distinct mechanisms of action compared to traditional monoamine-based or monoamine...

Adjunctive use of mindfulness-based mobile application in depression: randomized controlled study.

European Archives of Psychiatry and Clinical Neuroscience June 1, 2025 Jan Sarlon, Else Schneider, Annette B Brühl et al. 2 citations

Mindfulness-based interventions (MBI) are effective in relapse prevention in Major Depressive Disorder (MDD). Internet-based interventions have been demonstrated to be effective in the treatment of MDD. Consequently, the integration of MBI through mobile applications emerges as a promising supplementary intervention for MDD, contributing to the augmentation of mental health services,...

Bridging the gap of brain and experience - Converging Neurophenomenology with Spatiotemporal Neuroscience.

Neuroscience & Biobehavioral Reviews June 1, 2025 Georg Northoff, Bianca Ventura 21 citations

Neuroscience faces the challenge of connecting brain and mind, with the mind manifesting in first-person experience while the brain's neural activity can only be investigated in third-person perspective. To connect neural and mental states, Neurophenomenology provides a methodological toolkit for systematically linking first-person subjective experience with third-person objective observations...

Mindfulness-based cognitive therapy versus treatment as usual after non-remission with NHS Talking Therapies high-intensity psychological therapy for depression: a UK-based clinical effectiveness and cost-effectiveness randomised, controlled, superiority trial.

The Lancet Psychiatry June 1, 2025 Thorsten Barnhofer, Barnaby D. Dunn, Clara Strauss et al. 9 citations

Non-remission after psychological therapy for major depressive disorder is common, yet there are no established further-line treatments. In the UK National Health Service (NHS) Talking Therapies programme, about 50% of patients with depression who come to the end of the stepped care pathway do not show remission of symptoms. We aimed to investigate whether mindfulness-based cognitive therapy...

Exploring the Neuroprotective and Neuropsychiatric Symptom Management Potential of Ketamine in Alzheimer's Disease.

Cureus June 1, 2025 Amy Avakian, Zachary I Merhavy 1 citation

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, synaptic dysfunction, and neuroinflammation. Despite extensive research, current therapeutic options offer limited symptomatic relief without altering disease progression. Ketamine, an N-methyl-D-aspartate receptor (NMDAR) antagonist traditionally used as an anesthetic, has garnered...

DOI: 10.7759/cureus.86855 (opens in new tab) Full text (opens in new tab) Depression Alzheimer's disease  Alzheimer’s dementia Anesthesia +15

Fixed dose combination dextromethorphan-bupropion: A hope for treatment resistant depression (TRD).

Indian Journal of Psychiatry June 1, 2025 Ranjan Das, Rajarshi Chakravarty, Varaha V Gantait et al. 4 citations

Treatment resistant depression (TRD) has been identified as non-response to depression with adequate dose and trial of two antidepressant medications of different classes. Near about 30% depressive patients are TRD cases. Olanzapine-fluoxetine combination, rTMS, Intravenous ketamine and Electroconvulsive therapy have been till now studied in TRD. Dextromethorphan-bupropion is a newer...

DOI: 10.4103/indianjpsychiatry_315_25 (opens in new tab) Full text (opens in new tab) Dextromethorphan-bupropion Treatment resistant depression Severe depression New approach +2

The antidepressant-like activity of ketamine in the rat chronic mild stress model requires activation of cortical 5-HT 1A receptors.

Behavioural Pharmacology June 1, 2025 Ronan Depoortère, Mariusz Papp, Piotr Gruca et al. 2 citations

Ketamine displays efficacious rapid-acting antidepressant (RAAD) activity in the rat chronic mild stress (CMS) model. It rapidly reverses anhedonia (CMS-induced sucrose consumption deficit) and attenuates working memory deficit (novel object recognition: NOR) following both systemic (intraperitoneal, i.p.) administration or local administration in the prefrontal cortex (PFC). However, the...

DOI: 10.1097/FBP.0000000000000809 (opens in new tab) Full text (opens in new tab) Biased agonist Chronic mild stress Rat Depression treatment +3

Esketamine Nasal Spray in Major Depressive Disorder: A Meta-Analysis of Randomized Controlled Trials.

Clinical Pharmacology & Therapeutics June 1, 2025 Zhibin Wang, Lili Jiang, Wenzhuang Ma et al. 8 citations

Despite being approved by the US FDA and the EU European Medicines Agency, the performance of esketamine nasal spray as an adjunctive therapy with an antidepressant in major depressive disorder is still controversial. Comprehensive retrieval in Embase, Pubmed, and Web of Science was conducted to identify randomized controlled trials comparing esketamine nasal spray versus control in major...

DOI: 10.1002/cpt.3555 (opens in new tab) Full text (opens in new tab) Mental health Depression treatment Medical breakthrough Antidepressants +1

The Effect of Ketamine-Assisted Group Therapy on Treatment-Resistant Mental Health Conditions in Firefighters: A Prospective Observational Case Series.

Journal of Occupational and Environmental Medicine June 1, 2025 Vivian Wl Tsang, Michelle Cq Lin, Cassandra M Choles et al. 4 citations

Firefighters display elevated risk for diagnoses of mental health illnesses. Psychedelic-assisted therapies show promise in the treatment of clinically challenging conditions. This observational case series analyzed data from firefighters with mental health diagnoses who participated in a 12-week ketamine-assisted group therapy treatment plan. Questionnaire scores (Generalized Anxiety Disorder...

Measuring suicidal behavior in the era of rapid-acting antidepressants: A systematic review of ketamine studies.

Psychiatry Research June 1, 2025 Flávia Vieira, Ana Teresa Caliman-Fontes, Breno Souza-Marques et al.

Assessment measures for suicidal behavior range from depression scales to longer suicide-specific instruments. In this review, we systematically summarize and discuss the currently used instruments for assessing suicidal behavior in the context of ketamine and its enantiomers. We searched Medline/PubMed, Embase, and PsycINFO databases for ketamine (and its enantiomers) human studies exploring...

Single subanesthetic dose of ketamine exerts antioxidant and antidepressive-like effect in ACTH-induced preclinical model of depression.

Molecular and cellular neurosciences June 1, 2025 Ana Ivanović, Jelena Petrović, Dušanka Stanić et al. 3 citations

Hyperactivity of the hypothalamic-pituitary-adrenal (HPA) axis and oxidative stress represent important mechanisms that have been implicated in etiopathology of depression. Although first antidepressants were introduced in clinical practice more than six decades ago, approximately 30 % of patients with a diagnosis of depression show treatment resistance. A noncompetitive N-methyl-d-aspartate...

Ketamine for unipolar depression: A systematic review of efficacy and safety.

Australasian Psychiatry June 1, 2025 Tharshanan Edwin Peiris, Amrit Pokhrel, Yuvaraj Paudel 2 citations

BackgroundUnipolar depression is a prevalent mental health disorder with persistent, treatment-resistant symptoms. Traditional antidepressants take weeks to show effects, underscoring the need for faster alternatives. Ketamine, originally an anaesthetic, has emerged as a rapid-acting antidepressant.ObjectiveThis systematic review evaluates ketamine's efficacy and safety in unipolar...